Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPSANTOS, Adriana Nancy Medeiros dosFARIAS-IAO, Daniela SouzaBENSENOR, Isabela M.GOULART, Alessandra C.BRUNONI, Andre R.VIANA, Maria CarmenLOTUFO, Paulo A.SUEMOTO, Claudia Kimie2023-08-162023-08-162023EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.79, n.7, p.927-934, 20230031-6970https://observatorio.fm.usp.br/handle/OPI/54561ObjectivesPotentially inappropriate medications (PIM), especially those with potential effects on the central nervous system, can increase the risk of cognitive impairment. We investigated the association of the use of PIM and PIM that may impair cognition (PIM-Cog) with cognitive performance among older adults.MethodsIn this cross-sectional study with 2,626 participants, PIM and PIM-Cog were defined by the 2019 American Geriatrics Society Beers criteria. We calculated global cognition and memory, verbal fluency, and Trail Making Test B version (TMT-B) z-scores. Linear regression models adjusted for sociodemographic and clinical variables were used to investigate the association between PIM and cognition.Results27% and 7% of the sample (mean age = 65.1 +/- 4.1 years old, 54% women, and 61% White) used at least one PIM and PIM-cog, respectively. PIM was associated with poor performance in the TMT-B (beta = -0.17, 95% Cl = -0.29; -0.05, p = 0.007). PIM-Cog was also associated with poor TMT-B performance (beta = -0.08, 95% Cl = -0.15; -0.01, p = 0.025).ConclusionThe use of PIM and PIM-Cog was associated with poor executive function among older adults. The review of PIM use and the deprescription of these drugs may be an effective way to improve cognitive function.engrestrictedAccessPotentiallyInappropriateMedicationCognitionDementiaDrug utilizationcriteriaarticleCopyright SPRINGER HEIDELBERG10.1007/s00228-023-03504-5Pharmacology & Pharmacy1432-1041